Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Feature|Articles|August 26, 2026
Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations
Author(s)Raviv Pryluk
Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk.
Advertisement
Advertisement
Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your biostatistician pulls up a standard power calculation, someone picks an effect size that feels reasonable, say, a 30% improvement over placebo, and the software produces a sample size. The meeting ends. The number gets locked in.
Related to this article
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.
CGT commercial trajectories are set years before approval — and every development decision is an access decision.
GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm.
Dr. Elena Christofides on why cortisol dysregulation may be the hidden reason GLP-1s fail — and what to do when patients don't respond.
Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.
Advertisement
Advertisement